§ Jim DobbinTo ask the Secretary of State for Health in what year and in which area health authority each of the fatal suspected adverse reactions associated with the use of Mifegyne were reported; what age the women whose deaths gave rise to the reports of fatal suspected adverse reactions associated with the use of Mifegyne were; and what the post mortems concluded was the cause of death in each case. [167257]
§ Ms Rosie WintertonAs with all medicines, the safety of Mifegyne (mifepristone) is continuously monitored by the Medicines and Healthcare products Regulatory Agency (MHRA). To date, the MHRA has received two reports of suspected adverse drug reactions (ADRs) with a fatal outcome.
In line with the "Code of Practice on Access to Government Information", we are unable to release any information that may possibly enable any patient to be identified and, in cases such as these, cause further unnecessary distress to the family. I am, therefore, unable to provide my hon. Friend with specific details concerning these cases.